SK bioscience to invest $3 million to Fina Biosolutions
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Under the deal, FinaBio will supply its own technologies to SK bioscience where it can "expand its businesses to other sectors including conjugate vaccine development services, reagents and technologies."
"We are delighted to continue developing partnerships with global firms that have next-generation vaccine technology," said SK bioscience CEO Ahn Jae-yong. "Through our mid- to long-term collaboration with FinaBio, we will advance the vaccines we are developing to the next level and strengthen our competitiveness for global market expansion."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SK bioscience will invest $3 million in Fina Biosolutions, a Maryland-based conjugate vaccine developer, the Korean company said Tuesday.
The details about the stake have not been disclosed. With this acquisition, SK bioscience will become FinaBio’s first and sole strategic investor.
Founded in 2006, FinaBio specializes in the research and development of conjugate vaccines for pneumonia, meningococcal disease and typhoid.
The U.S. company particularly owns critical technology to manufacture Cross-Reacting Material 197, a nontoxic mutant of the diphtheria toxin widely used as a carrier protein in conjugate vaccines.
Under the deal, FinaBio will supply its own technologies to SK bioscience where it can "expand its businesses to other sectors including conjugate vaccine development services, reagents and technologies."
FinaBio is also developing next-generation conjugation technology that targets the desired location for antigen binding, which is helpful in boosting immunogenicity and productivity.
The developer is in partnership with various global companies and research institutions including the Serum Institute of India, the Chengdu Institute of Biology in China and Inventprise in the United States to supply its conjugation technology.
“We are delighted to continue developing partnerships with global firms that have next-generation vaccine technology," said SK bioscience CEO Ahn Jae-yong. "Through our mid- to long-term collaboration with FinaBio, we will advance the vaccines we are developing to the next level and strengthen our competitiveness for global market expansion.”
BY SARAH CHEA [chea.sarah@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- NCT's Moon Tae-il indicted for alleged sexual assault of woman with two other men
- From celebrity chef to dim sum queen: Meet the Top 8 of 'Culinary Class Wars' (Part 1)
- Chefs prepare for 'cooking hell' in 'Culinary Class Wars' final episodes
- From maniac to 'matfia:' Meet the Top 8 of 'Culinary Class Wars' (Part 2)
- Mount Seorak's fall foliage arrives in October for first time in 13 years
- Samsung apologizes for disappointing Q3 results
- 2NE1's long-awaited 'Welcome Back' concert gives fans nostalgia overload
- Korea, Philippines form 'strategic partnership' during Yoon's state visit
- Girl group aespa to release members' solo tracks on Oct. 9
- Enhypen's 'Walk The Line' world tour hits the ground running at Goyang Stadium